
Need and Use of Information Collection: The purpose of the ASD portfolio analysis is to collect research funding data from U.S. and international ASD research funders, to assist the Interagency Autism Coordinating Committee (IACC) in fulfilling the requirements of the Combating Autism Act, and to inform the committee and interested stakeholders of the funding landscape and current directions for ASD research. Specifically, these analyses will examine the extent to which current funding and research topics align with the IACC Strategic Plan for ASD Research. The findings will help guide future funding priorities by outlining current gaps and opportunities in ASD research as well as serving to highlight annual activities and research progress.

OMB approval is requested for three years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 419.

ESTIMATED ANNUALIZED BURDEN HOURS

<table>
<thead>
<tr>
<th>Type of respondents (funders)</th>
<th>Number of respondents</th>
<th>Number of response per respondent</th>
<th>Average Time per Response (in hours)</th>
<th>Total burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S. Federal</td>
<td>26</td>
<td>36</td>
<td>15/60</td>
<td>234</td>
</tr>
<tr>
<td>U.S. Private</td>
<td>12</td>
<td>54</td>
<td>15/60</td>
<td>162</td>
</tr>
<tr>
<td>International Government</td>
<td>4</td>
<td>14</td>
<td>15/60</td>
<td>14</td>
</tr>
<tr>
<td>International Private</td>
<td>4</td>
<td>9</td>
<td>15/60</td>
<td>9</td>
</tr>
</tbody>
</table>

Dated: March 26, 2013.

Sue Murrin,
Executive Officer, NIMH, NIH.

[FR Doc. 2013–12420 Filed 5–23–13; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications/contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, AIDS and Cancer Specimen Resource (ACSR)

Date: May 29, 2013

Time: 12:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications

Place: National Cancer Institute, Shady Grove, Shady Grove, 9609 Medical Center Drive, Room 1E030, Rockville, MD 20850 (Telephone Conference Call)

Contact Person: Thaddeus F. Loughlin, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Rockville, MD 20850 (Telephone Conference Call)

Name of Committee: National Cancer Institute Special Emphasis Panel, RNA Biosensors

Date: June 13, 2013

Time: 1:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications

Place: National Cancer Institute, Shady Grove, Shady Grove, 9609 Medical Center Drive, Room 1E030, Rockville, MD 20850 (Telephone Conference Call)

Contact Person: Bratin K. Saha, Ph.D., Scientific Review Officer, Program Coordination and Referral Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W756, Bethesda, MD 20892, 240–276–6411, sbahab@mail.nih.gov

Name of Committee: National Cancer Institute Special Emphasis Panel, Innovative Technologies for Cancer Biospecimen Science

Date: June 12, 2013

Time: 12:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications

Place: National Cancer Institute—Shady Grove, Shady Grove, 9609 Medical Center Drive, Room 1E030, Rockville, MD 20850 (Telephone Conference Call)

Contact Person: Donald L Coppock, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W260, Bethesda, MD 20892, 240–276–6428, donald.coppock@nih.gov

Name of Committee: National Cancer Institute Special Emphasis Panel, RNA Biology

Date: June 25, 2013

Time: 1:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications

Place: National Cancer Institute, Shady Grove, Shady Grove, 9609 Medical Center Drive, Room 6W034, Rockville, MD 20850 (Telephone Conference Call)
DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of a Start-Up Exclusive Patent License Agreement: Treatment of Graves’ Disease, Hyperthyroidism and Thyroid Cancer

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-Up Exclusive Patent License to Nova Therapeutics LLC, a company having a place of business in Delaware, to practice the inventions embodied in the following patent applications:


The patent rights in this invention concerns small molecule compounds that antagonize the activity of the thyroid stimulating hormone receptor (‘‘TSHR’’). These antagonists are classified into two functional categories: (a) Neutral antagonists that prevent TSHR from being turned on, and (b) inverse agonists that turn off active TSHR. Both categories of antagonists may be useful in treating hyperthyroidism and Graves’ disease, an autoimmune disease that is commonly associated with hyperthyroidism. In addition, certain small molecule compounds that function as inverse agonists of TSHR may be effective in reducing the recurrence of thyroid cancer.

The prospective Start-Up Exclusive Patent License is being considered under the small business initiative launched on 1 October 2011 and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective Start-Up Exclusive Patent License may be granted unless the NIH receives written evidence and argument, within fifteen (15) days from the date of this published notice, that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Complete applications for a license in the prospective field of use that are filed in response to this notice will be treated as objections to the grant of the contemplated Start-Up Exclusive Patent License. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: May 20, 2013.

Richard U. Rodriguez,
Director, Division of Technology Development & Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2013–12375 Filed 5–23–13; 8:45 am]